Iterum Therapeutics Plc (NASDAQ:ITRM) has a beta value of 2.25 and has seen 2.16 million shares traded in the last trading session. The company, currently valued at $26.20M, closed the last trade at $1.22 per share which meant it lost -$0.07 on the day or -5.43% during that session. The ITRM stock price is -104.92% off its 52-week high price of $2.50 and 46.72% above the 52-week low of $0.65. If we look at the company’s 10-day average daily trading volume, we find that it stood at 13.15 million shares traded. The 3-month trading volume is 2.28 million shares.
The consensus among analysts is that Iterum Therapeutics Plc (ITRM) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Sporting -5.43% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ITRM stock price touched $1.22 or saw a rise of 33.7%. Year-to-date, Iterum Therapeutics Plc shares have moved -38.07%, while the 5-day performance has seen it change -35.11%. Over the past 30 days, the shares of Iterum Therapeutics Plc (NASDAQ:ITRM) have changed 22.49%. Short interest in the company has seen 0.21 million shares shorted with days to cover at 1.16.
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Figures show that Iterum Therapeutics Plc shares have outperformed across the wider relevant industry. The company’s shares have lost -22.78% over the past 6 months, with this year growth rate of 59.80%, compared to 18.30% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.62% over the past 5 years.
ITRM Dividends
Iterum Therapeutics Plc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
Insiders own 1.81% of the company shares, while shares held by institutions stand at 3.05% with a share float percentage of 3.10%. Investors are also buoyed by the number of investors in a company, with Iterum Therapeutics Plc having a total of 16.0 institutions that hold shares in the company. The top two institutional holders are BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC with over 66.0 shares worth more than $76.0. As of 2024-06-30, BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC held 0.0004% of shares outstanding.
